Amy Warriner
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1982817508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Medtronic at 50.5% of the total. Reporting peaked in 2023 at $137 and has fallen 70.3% since, to $41 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 8 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$122
- Novo Nordisk$81
- Neurocrine Biosciences, Inc.$24
- Lilly USA, LLC$15
Across 48 payments — averaging $3795.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$69K
- AbbVie$63K
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- AstraZeneca$10K
- Bayer$7K
What the payments were for
- Food & beverage$21890%
- Education$2410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $122 |
| Novo Nordisk | 5 | $81 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$122
How this compares
$242 in reported general payments places this provider in the 10th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 64 | $254,483 |
| MounjaroTirzepatide | 221 | $251,523 |
| JardianceEmpagliflozin | 128 | $131,853 |
| TrulicityDulaglutide | 97 | $128,422 |
| OzempicSemaglutide | 95 | $108,718 |
| Teriparatide | 20 | $47,449 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $34,156 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $25,330 |
| WegovySemaglutide | 15 | $21,054 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $16,768 |
| JanuviaSitagliptin Phosphate | 17 | $12,962 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $10,401 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $7,536 |
| InvokanaCanagliflozin | 12 | $6,725 |
| Zoledronic AcidZoledronic Acid/Mannitol-Water | 62 | $5,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro, Trulicity | $15 | $634,428382 claims |
| Novo NordiskOzempic, Wegovy | $81 | $129,773110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.